Farallon Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Farallon Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-150,000	Closed	-$21.9M	–	176
2023 Q1	$21.9M	Sell	150,000 -79,800	-35%	-$11.8M	0.12%	78
2022 Q4	$36.6M	Sell	229,800 -307,700	-57%	-$45.1M	0.22%	70
2022 Q3	$71.6M	Sell	537,500 -382,600	-42%	-$58.2M	0.39%	65
2022 Q2	$144M	Buy	920,100 +591,100	+180%	+$91M	0.78%	42
2022 Q1	$51.2M	Sell	329,000 -102,021	-24%	-$14.8M	0.25%	69
2021 Q4	$54.9M	Sell	431,021 -143,886	-25%	-$18.9M	0.27%	64
2021 Q3	$74.9M	Buy	+574,907	New	+$86.9M	0.35%	61

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Farallon Capital Management's JAZZ Position: Q2 2023 in Review

Farallon Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 150,000 shares — an estimated $21.9M sold.

Farallon Capital Management first reported a position in JAZZ in Q3 2021 and held it in 7 quarters. The position peaked at $144M in Q2 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

Farallon Capital Management reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Farallon Capital Management sold 150,000 Jazz Pharmaceuticals shares in Q2 2023, an estimated $21.9M.
Farallon Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 7 quarters.
Farallon Capital Management's Jazz Pharmaceuticals position peaked at $144M in Q2 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Farallon Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.